Ophirex, Inc.

First in Class: Begin treating any snakebite, any place, any time with Ophirex antidotes--Oral, IV and SC for human and veterinary use. A $30BB market.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Corte Madera, CA, US
  • Currency USD
  • Founded January 2015
  • Employees 2
  • Incorporation Type C-corp

Company Summary

>75% of snakebite deaths occur outside the hospital.

Our solution is a pipeline of the world's first field antidotes to snakebite and lead compounds almost ready for human clinical trials as well as deployment for veterinary use.

The indication: "ANY snakebite". Unlike epipen, ours can be taken orally. We also have IV (hospital/military use) and subcutaneous versions for veterinary use. The accessible Global Market should be well over $30BB.

Team

Advisors

  • Don Weil
    Philip Bickler, MD, PhD
    Unconfirmed
    Jerry Harrison
    Unconfirmed
  • Jack Tupman, MBA
    Unconfirmed
    Kimberly Baltzell, PhD, RN, MS
    Unconfirmed

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free